Want to see IN:BAFNAPH full AI Analyst Report?
BAFNAPH Stock Chart & Stats
₹154.65
-₹1.34(-1.60%)
At close: 4:00 PM EST
₹154.65
-₹1.34(-1.60%)
Day’s Range― - ―
52-Week Range₹77.01 - ₹234.15
Previous CloseN/A
Volume2.58K
Average Volume (3M)1.19K
Market Cap
₹5.32B
Enterprise Value₹4.06B
Total Cash (Recent Filing)₹19.67M
Total Debt (Recent Filing)₹324.03M
Price to Earnings (P/E)47.1
Beta0.70
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.70
Shares Outstanding23,656,336
10 Day Avg. Volume1,123
30 Day Avg. Volume1,187
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)2.69
Price to Sales (P/S)1.72
P/FCF Ratio-19.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue GrowthConsistent multi-year top-line expansion from 2021–2026 indicates the company has scaled sales and market reach. Durable revenue growth supports fixed-cost absorption, manufacturing utilization and reinvestment potential, underpinning longer-term earnings capacity if margin stability improves.
Reasonable Balance Sheet And Equity BuildA steadily building equity base and only moderate leverage provide financial cushion and access to capital. This structural strength supports capex, regulatory compliance and potential international expansion, offering resilience versus shocks and enabling strategic investments over the medium term.
Proven Ability To Restore ProfitabilityHistorical high margins and a sharp net income rebound in 2026 show operational flexibility to recover profitability via pricing, mix or cost actions. That capability suggests management can drive margin improvement repeatably, an important durable advantage if product mix supports higher-margin growth.
Bears Say
Persistent Negative Free Cash FlowRepeated negative free cash flow across most years materially reduces internal funding for capex, debt paydown or shareholder returns. Structural FCF deficits increase reliance on external financing and constrain strategic flexibility, raising medium-term funding and execution risk if not reversed.
Inconsistent Operating Cash FlowVolatile operating cash flow, including a negative year, signals uneven earnings quality and working-capital swings. Persistent OCF inconsistency complicates forecasting, raises liquidity pressure and may force more frequent external funding, impairing the company’s ability to self-fund growth reliably.
Rising Debt Trend Into 2026Notable debt increases into 2026 raise leverage against a weak cash conversion profile. Growing debt with intermittent cash generation elevates refinancing and interest-rate risk and could constrain future capital allocation, forcing prioritization of debt service over growth or shareholder returns.
Bafna Pharmaceuticals Limited News
BAFNAPH FAQ
What was Bafna Pharmaceuticals Limited’s price range in the past 12 months?
Bafna Pharmaceuticals Limited lowest stock price was ₹77.01 and its highest was ₹234.15 in the past 12 months.
What is Bafna Pharmaceuticals Limited’s market cap?
Bafna Pharmaceuticals Limited’s market cap is ₹5.32B.
When is Bafna Pharmaceuticals Limited’s upcoming earnings report date?
Bafna Pharmaceuticals Limited’s upcoming earnings report date is Aug 07, 2026 which is in 33 days.
How were Bafna Pharmaceuticals Limited’s earnings last quarter?
Bafna Pharmaceuticals Limited released its earnings results on May 29, 2026. The company reported ₹1.16 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.16.
Is Bafna Pharmaceuticals Limited overvalued?
According to Wall Street analysts Bafna Pharmaceuticals Limited’s price is currently Overvalued.
Does Bafna Pharmaceuticals Limited pay dividends?
Bafna Pharmaceuticals Limited pays a Notavailable dividend of ₹0.6 which represents an annual dividend yield of N/A. See more information on Bafna Pharmaceuticals Limited dividends here
What is Bafna Pharmaceuticals Limited’s EPS estimate?
Bafna Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bafna Pharmaceuticals Limited have?
Bafna Pharmaceuticals Limited has 23,656,336 shares outstanding.
What happened to Bafna Pharmaceuticals Limited’s price movement after its last earnings report?
Bafna Pharmaceuticals Limited reported an EPS of ₹1.16 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.372%.
Which hedge fund is a major shareholder of Bafna Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:BAFNAPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences LLP.
Technical Analysis
Aarey Drugs & Pharmaceuticals Ltd.
―
Alpa Laboratories Limited
―
Bal Pharma Limited
―
Krebs Biochemicals & Industries Ltd.
―
Mangalam Drugs & Organics Ltd.
―